The DOI matches its Crossref record.
Fatigue therapy in multiple sclerosis: Results of a double‐blind, randomized, parallel trial of amantadine, pemoline, and placebo
Abstract
OBJECTIVE: To determine the relative efficacy of amantadine, pemoline, and placebo in treatment of multiple sclerosis (MS)-related fatigue. BACKGROUND: Fatigue is a complication of MS. Both pemoline and amantadine have been used to treat MS fatigue, but their relative efficacy is not known. METHODS: Amantadine, pemoline, and placebo were compared in a randomized, double-blind, placebo-controlled study using a parallel-group design. Ninety-three ambulatory MS patients completed the study. Primary outcome measures were the fatigue severity scale (FSS); the MS-specific fatigue scale (MS-FS); and subjective response determined by verbal self-report. Secondary outcome measures consisted of assessments of sleep, depression, and vitality. Repeated-measures analysis of variance with planned post-hoc contrasts and Fisher's exact test were used to compare treatment response. RESULTS: Amantadine-treated patients showed a significantly greater reduction in fatigue, as measured by the MS-FS, than did patients treated with placebo (p = 0.04). By verbal report at the end of the study, 79% of patients treated with amantadine versus 52% treated with placebo and 32% treated with pemoline preferred drug therapy compared with no treatment (p = 0.03). No significant differences in any primary outcome measures were noted between pemoline and placebo. Neither amantadine nor pemoline affected sleep or depression relative to placebo. CONCLUSION: Amantadine was significantly better than placebo in treating fatigue in MS patients, whereas pemoline was not. The benefit of amantadine was not due to changes in sleep, depression, or neurologic disability.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications
Felger, J. C., & Lotrich, F. E. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.060 · Cited by 1,180
Fatigue and fatigability in neurologic illnesses: Proposal for a unified taxonomy
Kluger, B. M., Krupp, L. B., & Enoka, R. M. (2013) · Neurology · doi:10.1212/wnl.0b013e31827f07be · Cited by 1,036
Self-citationValidation of the Fatigue Severity Scale in a Swiss Cohort
Valko, P. O., Bassetti, C. L., Bloch, K. E., Held, U., & Baumann, C. R. (2008) · Sleep · doi:10.1093/sleep/31.11.1601 · Cited by 681
Penner, I., Raselli, C., Stöcklin, M., Opwis, K., Kappos, L., & Calabrese, P. (2009) · Multiple Sclerosis Journal · doi:10.1177/1352458509348519 · Cited by 593
Quality of life in patients with multiple sclerosis
Janardhan, V., & Bakshi, R. (2002) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(02)00312-x · Cited by 489
Metadata
- Authors
- Krupp, L. B., Coyle, P. K., Doscher, C., Miller, A., Cross, A. H., Jandorf, L., Halper, J., Johnson, B., Morgante, L., & Grimson, R.
- Venue
- Neurology
- Published
- 1995-11
- Volume
- 45
- Issue
- 11
- Pages
- 1956-1961
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W1983334940
- Cited by
- 359
- References
- 0
- FWCI
- 3.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fatigue therapy in multiple sclerosis: Results of a double‐blind, randomized, parallel trial of amantadine, pemoline, and placebo. https://app.cochat.ai/papers/10.1212/wnl.45.11.1956
- The paper
- Krupp, L. B., Coyle, P. K., Doscher, C., Miller, A., Cross, A. H., Jandorf, L., Halper, J., Johnson, B., Morgante, L., & Grimson, R. (1995). Fatigue therapy in multiple sclerosis: Results of a double‐blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology. https://doi.org/10.1212/wnl.45.11.1956
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.